UCSF Research 2020
P2-060 - Re-estimation of drug-specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q-ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab; paper presented on 17 July, 2023 at the Alzheimer's Association International Conference (AAIC).